SRD5A2 and benign prostatic hyperplasia: The results of this studyreveal that the liposomal formulation based on enzyme immobilizationof Cas9 protein using CRISPR technology, an innovative gene-editingtool for SRD5α2 suppression, might be an alternative treatmentoption for prostate cancer or BPH treatment without current drug sideeffects.